

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

New for 2026

- No applicable changes for this measure

Definition

Percentage of members ages 18 and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of the treatment period.

| Plans(s) affected | Quality program(s) affected | Collection and reporting method |
|--|--|--|
| <ul style="list-style-type: none"> • Commercial • Medicaid • Medicare | <ul style="list-style-type: none"> • NCQA Health Plan Ratings | <p>Administrative</p> <ul style="list-style-type: none"> • Claim/encounter data • Pharmacy data |

Medications

To comply with this measure, a member must have remained on 1 of the following antipsychotic medications for at least 80% of the treatment period.

Oral antipsychotic medications

| Drug category | Medications |
|--|---|
| Miscellaneous antipsychotic agents (oral) | <ul style="list-style-type: none"> • Aripiprazole • Asenapine • Brexpiprazole • Cariprazine • Clozapine • Haloperidol • Iloperidone • Loxapine • Lumateperone • Lurasidone • Molindone • Olanzapine • Paliperidone • Quetiapine • Risperidone • Ziprasidone |

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT® is a registered trademark of the American Medical Association. UnitedHealthcare will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with UnitedHealthcare.

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) (cont.)

| Drug category | Medications |
|--|---|
| Phenothiazine antipsychotics (oral) | <ul style="list-style-type: none"> • Chlorpromazine • Fluphenazine • Perphenazine • Prochlorperazine • Thioridazine • Trifluoperazine |
| Psychotherapeutic combinations (oral) | <ul style="list-style-type: none"> • Amitriptyline-perphenazine |
| Thioxanthenes (oral) | <ul style="list-style-type: none"> • Thiothixene |
| Long-acting injections 14-day supply | <ul style="list-style-type: none"> • Risperidone (excluding Perseris®) |
| Long-acting injections 28-day supply | <ul style="list-style-type: none"> • Aripiprazole • Aripiprazole lauroxil • Fluphenazine decanoate • Haloperidol decanoate • Olanzapine |
| Long-acting injections 30-day supply | <ul style="list-style-type: none"> • Risperidone (Perseris®) |
| Long-acting injections 35-day supply | <ul style="list-style-type: none"> • Paliperidone palmitate (Invega Sustenna) |
| Long-acting injections 104-day supply | <ul style="list-style-type: none"> • Paliperidone palmitate (Invega Trinza®) |
| Long-acting injections 201-day supply | <ul style="list-style-type: none"> • Paliperidone palmitate (Invega Hafyera™) |

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT® is a registered trademark of the American Medical Association. UnitedHealthcare will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with UnitedHealthcare.

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) (cont.)

Required exclusion(s)

| Exclusion | Time frame |
|--|---|
| <ul style="list-style-type: none"> Members in hospice or using hospice services Members who died Diagnosis of dementia Members ages 81 and older as of Dec. 31 of the measurement year who had at least 2 diagnoses of frailty* on different dates of service Members who did not have at least 2 antipsychotic medication dispensing events. There are 2 ways to identify dispensing events: by Claim/encounter data and by Pharmacy data. | <p>Any time during the measurement year</p> |
| <p>Members ages 66-80 as of Dec. 31 of the measurement year with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to qualify as an exclusion:</p> <ul style="list-style-type: none"> Frailty: At least 2 diagnoses of frailty on different dates of service during the measurement year. Do not include claims where the frailty diagnosis was from an independent lab (POS 81). Advanced Illness: Indicated by 1 of the following: <ul style="list-style-type: none"> At least 2 diagnoses of advanced illness on different dates of service during the measurement year or year prior. Do not include claims where the advanced illness diagnosis was from an independent lab (POS 81). Dispensed dementia medication: Donepezil, Donepezil-Memantine, Galantamine, Rivastigmine or Memantine | <ul style="list-style-type: none"> Frailty diagnoses must be in the measurement year and on different dates of service Advanced illness diagnosis must be in the measurement year or year prior to the measurement year |
| <p>Medicare members ages 66 and older as of Dec. 31 of the measurement year who are either:</p> <ul style="list-style-type: none"> Enrolled in an Institutional Special Needs Plan (I-SNP) Living long term in an institution* | <p>Any time during the measurement year</p> |

* Supplemental and medical record data may not be used for the frailty with advanced illness or institutional living exclusions.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT® is a registered trademark of the American Medical Association. UnitedHealthcare will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with UnitedHealthcare.

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) (cont.)

Tips and best practices to help close this care opportunity

This measure focuses on medication compliance.

- Encourage patients to take medications as prescribed
- Offer tips to patients such as:
 - Take medication at the same time each day
 - Use a pill box
 - Enroll in a pharmacy automatic-refill program

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT® is a registered trademark of the American Medical Association. UnitedHealthcare will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with UnitedHealthcare.